Table 1 Key assumptions made in the CHX cost-consequence model
From: Cost and consequences of using 7.1 % chlorhexidine gel for newborn umbilical cord care in Kenya
Input | Assumptions |
|---|---|
Incidence rates of omphalitis with DCC | DCC, and the associated incidence rate of omphalitis, reflects the standard of care and therefore the rate in clinical practice in Kenya. This is due to the limitation in data available from robust clinical trials limiting the comparison of CHX to DCC only. Absolute cases of omphalitis avoided may be underestimated compared with clinical practice. |
Comparative efficacy: relative risk of omphalitis | The relative risk of omphalitis for CHX versus DCC in the base case is assumed based on data from the Cochrane review for the least severe category of omphalitis. |
Comparative efficacy: mortality | Not included in the model. Therefore, the effect of CHX is only applied to rates of omphalitis. |
Medications to treat omphalitis | Assumed to predominantly follow clinical opinion. Clinical practice may differ from guideline recommendations. |
Productivity loss | Calculated based on the average salary in Kenya and therefore average cost of time lost. |